Rheumnow Podcast
Ides of March (3.15.2024)
Mar 15, 2024
Exploring topics such as infections in patients on biologics, H. pylori infection and GI complications, IL-17 inhibitors and lupus management, vaccinations in rheumatology, and the impact of depression on all-cause mortality in RA patients.
22:26
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Non-serious infections should not stop biologic treatments as they resolve with minimal impact.
- TNF inhibitors users in Japan face low NTM infection rates but need monitoring for adverse events.
Deep dives
Infections and Biologics: Serious vs. Non-Serious
Research on biologics highlighted a significant difference between non-serious and serious infections. Non-serious infections, such as upper respiratory tract infections, were significantly more common than serious infections, with the former recurring steadily over time. The study emphasized that non-serious infections should not prompt halting biologic treatments, as they resolve before the drug's effects. Additionally, recurrent non-serious infections may warrant further investigations to address underlying reasons.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
